122 related articles for article (PubMed ID: 38430025)
21. Doxorubicin-Loaded Platelet Decoys for Enhanced Chemoimmunotherapy Against Triple-Negative Breast Cancer in Mice Model.
Dong H; Gao M; Lu L; Gui R; Fu Y
Int J Nanomedicine; 2023; 18():3577-3593. PubMed ID: 37409026
[TBL] [Abstract][Full Text] [Related]
22. Apoptosis-driven synergistic anti-cancer efficacy of ethyl acetate extract of Memecylon sisparense Gamble leaves and doxorubicin in in-vitro and in-vivo models of triple-negative breast cancer.
Uppu JL; Challa VS; Syamprasad NP; Manepalli P; Naidu V; Syed A; Roshan S; Tazneem B; Almalki WH; Alharbi KS; Gupta G
Pathol Res Pract; 2024 Jan; 253():155032. PubMed ID: 38176306
[TBL] [Abstract][Full Text] [Related]
23. Anti-cancer therapeutic benefit of red guava extracts as a potential therapy in combination with doxorubicin or targeted therapy for triple-negative breast cancer cells.
Liu HC; Chiang CC; Lin CH; Chen CS; Wei CW; Lin SY; Yiang GT; Yu YL
Int J Med Sci; 2020; 17(8):1015-1022. PubMed ID: 32410830
[TBL] [Abstract][Full Text] [Related]
24. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.
Chuang HC; Kapuriya N; Kulp SK; Chen CS; Shapiro CL
Breast Cancer Res Treat; 2012 Jul; 134(2):649-59. PubMed ID: 22678161
[TBL] [Abstract][Full Text] [Related]
25. Synergistic Effect of SH003 and Doxorubicin in Triple-negative Breast Cancer.
Woo SM; Kim AJ; Choi YK; Shin YC; Cho SG; Ko SG
Phytother Res; 2016 Nov; 30(11):1817-1823. PubMed ID: 27476488
[TBL] [Abstract][Full Text] [Related]
26. Combined doxorubicin and arctigenin treatment induce cell cycle arrest-associated cell death by promoting doxorubicin uptake in doxorubicin-resistant breast cancer cells.
Lee MG; Lee KS; Nam KS
IUBMB Life; 2023 Sep; 75(9):765-777. PubMed ID: 37492896
[TBL] [Abstract][Full Text] [Related]
27. The cyclin-dependent kinase inhibitor abemaciclib-induced hepatotoxicity: Insight on the molecular mechanisms in HepG2/THP-1 co-culture model.
Boran T; Zengin OS; Seker Z; Gunaydin Akyildiz A; Oztas E; Özhan G
Toxicol Lett; 2024 Jan; 391():1-12. PubMed ID: 37992977
[TBL] [Abstract][Full Text] [Related]
28. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
[TBL] [Abstract][Full Text] [Related]
29. Morin Sensitizes MDA-MB-231 Triple-Negative Breast Cancer Cells to Doxorubicin Cytotoxicity by Suppressing FOXM1 and Attenuating EGFR/STAT3 Signaling Pathways.
Maharjan S; Lee MG; Kim SY; Lee KS; Nam KS
Pharmaceuticals (Basel); 2023 Apr; 16(5):. PubMed ID: 37242455
[TBL] [Abstract][Full Text] [Related]
30. Quercetin-loaded solid lipid nanoparticles exhibit antitumor activity and suppress the proliferation of triple-negative MDA-MB 231 breast cancer cells: implications for invasive breast cancer treatment.
Hatami M; Kouchak M; Kheirollah A; Khorsandi L; Rashidi M
Mol Biol Rep; 2023 Nov; 50(11):9417-9430. PubMed ID: 37831347
[TBL] [Abstract][Full Text] [Related]
31. Trojan-Like Peptide Drug Conjugate Design and Construction for Application in Treatment of Triple-Negative Breast Cancer.
Xiao C; Han J; Bai J; Xia Y; Wang S
J Biomed Nanotechnol; 2021 Aug; 17(8):1554-1563. PubMed ID: 34544533
[TBL] [Abstract][Full Text] [Related]
32. Intracellular trafficking and cytotoxicity of a gelatine-doxorubicin conjugate in two breast cancer cell lines.
Alvi MM; Nicoletto RE; Eshmawi BA; Kim HK; Cammarata CR; Ofner CM
J Drug Target; 2020 Jun; 28(5):487-499. PubMed ID: 31601131
[TBL] [Abstract][Full Text] [Related]
33. Actinomycin D synergizes with Doxorubicin in triple-negative breast cancer by inducing P53-dependent cell apoptosis.
Yang H; Li S; Li W; Yang Y; Zhang Y; Zhang S; Hao Y; Cao W; Xu F; Wang H; Du G; Wang J
Carcinogenesis; 2024 Apr; 45(4):262-273. PubMed ID: 37997385
[TBL] [Abstract][Full Text] [Related]
34. Peptide-Drug Conjugate Targeting Keratin 1 Inhibits Triple-Negative Breast Cancer in Mice.
Ziaei E; Paiva IM; Yao SJ; Sarrami N; Mehinrad P; Lai J; Lavasanifar A; Kaur K
Mol Pharm; 2023 Jul; 20(7):3570-3577. PubMed ID: 37307328
[TBL] [Abstract][Full Text] [Related]
35. Enzalutamide Overcomes Dihydrotestosterone-Induced Chemoresistance in Triple- Negative Breast Cancer Cells
Alsawalha L; Ahram M; Abdullah MS; Dalmizrak O
Anticancer Agents Med Chem; 2022; 22(17):3038-3048. PubMed ID: 35579133
[TBL] [Abstract][Full Text] [Related]
36. Different sensitivities of senescent breast cancer cells to immune cell-mediated cytotoxicity.
Inao T; Kotani H; Iida Y; Kartika ID; Okimoto T; Tanino R; Shiba E; Harada M
Cancer Sci; 2019 Sep; 110(9):2690-2699. PubMed ID: 31250942
[TBL] [Abstract][Full Text] [Related]
37. Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells.
Yang F; Wang F; Liu Y; Wang S; Li X; Huang Y; Xia Y; Cao C
Life Sci; 2018 Nov; 213():149-157. PubMed ID: 30352240
[TBL] [Abstract][Full Text] [Related]
38. Inorganic Phosphate Prevents Erk1/2 and Stat3 Activation and Improves Sensitivity to Doxorubicin of MDA-MB-231 Breast Cancer Cells.
Sapio L; Sorvillo L; Illiano M; Chiosi E; Spina A; Naviglio S
Molecules; 2015 Sep; 20(9):15910-28. PubMed ID: 26340617
[TBL] [Abstract][Full Text] [Related]
39. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
[TBL] [Abstract][Full Text] [Related]
40. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
